Category Archives: Nano Medicine

Cancer, unfortunately, is widespread throughout the world. It affects millions of lives, in many different ways, on a daily basis. Before we dive into the topic of nanomedicine and nanoparticles, lets first look at the current state of cancer treatment.

Most therapeutic options for cancer are detrimental to the body They dont just kill cancer cells, they can also damage healthy tissues causing serious side effects.

Cancer chemotherapy drugs suffer from poor biodistribution and, therefore, require high doses. [1] Resistance can also develop to one or more of the drugs being used on a regular basis. This means that oncologists must continually develop new drug cocktails to keep treating their patients.

Some of the drugs used, particularly in later rounds of chemotherapy, may also be relatively ineffective.

So far, the benefits of chemotherapy have outweighed the risks but with the dawn of the age of nanomedicine and nanoparticles, the situation may soon change.

Nanomedicine is the medical application of nanotechnology. According to Johns Hopkins:

Nanomedicine can include a wide range of applications, including biosensors, tissue engineering, diagnostic devices, and many others. [It involves]harnessing nanotechnology to more effectively diagnose, treat, and prevent various diseases.

It also involves the development of new approaches to more efficiently deliver medications to the site of action with the aim of improving outcomes with less medication (and fewer medication side effects).

Nanoparticles are amongst the most promising treatment options in oncology, They have the potential to revolutionize the usual therapies by improving the usage and delivery of chemotherapy drugs [2].

The ability to control nanoparticle shape, size, and surface, as well as their ability to transport and deliver drugs to specific locations in the body, make nanoparticles highly useful in oncology[3].

Nanoparticles use has also spread to other areas of the medical world,[4] including:

Almost. Cancer is often debilitating with few treatment options that include surgery, chemotherapy, radiation, and immunotherapy. The side effects of these treatments can be detrimental to a patients way of living. They can often experience insomnia, nausea, vomiting, and weight loss among a long list of other adverse reactions [5].

With a cancer diagnosis and treatment, a patients quality of life can quickly nose-dive. But with nanomedicine, patients may experience a dramatic decrease in chemotherapy side effects, including a reduction of toxicity from the drugs used [6]. This, combined with all the other possible advantages of administering nanoparticles, makes nanomedicine an attractive new cancer therapy option.

Nanoparticles are attractive treatment options because their outer surfaces can be modified to attack specific cancer cells. They are biocompatible and biodegradable. They also offer increased stability to their drug payload[7].

Other possible advantages include:

There are three main types of nanoparticles [8] as follows:

Lipid-based nanoparticles have many advantages over other variations of nanoparticles. This accounts for their increased use in the delivery of drugs. Lipid-based nanoparticles have better biocompatibility than other nanoparticles. This means they work better with living tissue. Lipid-based nanoparticles are also more versatile, making them a better option in many therapies, like cancer treatments.

Liposomes are formulated with a wide range of natural, synthetic, and modified lipids to help them deliver drugs as well as contrast agents for medical imaging. Liposomes are used to treat cancer, fungal infections, vaccines, and more.

Polymeric nanoparticles are currently used for the following:

Polymer-based nanoparticles improve the efficiency of drugs as well as decrease drug side effects and toxicity.

Efficiently. The purpose of nanoparticles is to deliver drugs directly to the cancer cells and not the rest of the body. They are administered intravenously and are then moved around the body by the circulatory system.

Nanoparticles are designed to locate and then accumulate on the cancer tissue, penetrating through the walls of a tumor to deliver the chemotherapy drug they carry [8]. This way, the chemotherapy drug is delivered directly to the site of cancer versus distributed throughout the body. Mass distribution to both diseased and healthy tissues is usually the cause of drug side effects.

There are different methods of releasing the drugs being administered via nanomedicine [9]:

Nanoparticles can also be designed to transform under different conditions to either release or hold onto their drugs.

While widely used for cancer therapies, nanoparticles are also used for diagnostics, a type of nanomedicine referred to as nanodiagnostics[10]. Several nanoparticle formulations have already been designed for diagnostic use only. Though currently in limited use, nanodiagnostics is a growing field with imaging applications, such as use in magnetic resonance monitoring of tumor blood vessels and coronary arteries in patients.

On top of diagnostics, nanoparticles are also used in research opportunities, the treatment of cardiovascular diseases[11], and theranostics, which is a term used to describe pre-clinical research and trials of drug therapies and other treatments[12].

The production and use of nanoparticles face many challenges [13], including:

The creation process for lipid-based nanoparticles has a significant variation between each batch developed.

The manufacturing process is challenging to develop and maintain to the point that significant, quality nanoparticles can be produced.

The production of nanoparticles is time-consuming and extremely labor-intensive, requiring specialized knowledge and tools.

Related content: Why Drug Discovery is So Hard and High Risk

Nanoparticles are intended to maximize the benefit/risk ratio of therapies. Rather than causing many debilitating symptoms in the hopes of curing one disease, like current cancer treatments, nanoparticles are designed to minimize any side effects while treating that same disease.

But the technology isnt 100 percent ready for prime time yet. More research is needed and more dollars must be spent on analyzing both the effectiveness of nanomedicine as well as the long-term effects on the body.

While lipid-based nanoparticles are the most promising prospect because they are made of natural elements and have more advantages than other types of nanoparticles, they are not yet a perfect solution for drug delivery. We need more significant investments in clinical trials in both the government and private sectors to advance the technology.

Nanomedicine is used to treat a variety of different diseases and conditions, but it is in the oncology segment where nanoparticles see the most use and the most promise. To date, there are 51 nanopharmaceuticals approved for use in clinical practice[14]. More are being studied in clinical trials for cancer and other diseases.

Clearly, nanomedicine is a field to watch closely. I believe with continual research, trials, and advancements, the future of nanomedicine and nanoparticles is bright.

****

**Love our content? Want more stories about Cancer Treatments, Drug Delivery Technologies, and New Innovations? SIGN UP FOR OUR WEEKLY NEWSLETTER HERE**

****

Related content: Why Drug Discovery is So Hard and High Risk

References:

[1] Torchilin, V.P. and Lukyanov, A.N., 2003. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug discovery today, 8(6), pp.259-266..

[2]Shi, J., Kantoff, P.W., Wooster, R. and Farokhzad, O.C., 2017. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 17(1), p.20.

[3] Cho, K., Wang, X.U., Nie, S. and Shin, D.M., 2008. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research, 14(5), pp.1310-1316.

[4] Heiligtag, F.J. and Niederberger, M., 2013. The fascinating world of nanoparticle research. Materials Today, 16(7-8), pp.262-271.

[5] Griffin, A.M., Butow, P.N., Coates, A.S., Childs, A.M., Ellis, P.M., Dunn, S.M. and Tattersall, M.H.N., 1996. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Annals of oncology, 7(2), pp.189-195.

[6] Landesman-Milo, D., Ramishetti, S. and Peer, D., 2015. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer and Metastasis Reviews, 34(2), pp.291-301.

[7] Doane, T.L. and Burda, C., 2012. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chemical Society Reviews, 41(7), pp.2885-2911.

[8] Singh, R. and Lillard Jr, J.W., 2009. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology, 86(3), pp.215-223.

[9] Mura, S., Nicolas, J. and Couvreur, P., 2013. Stimuli-responsive nanocarriers for drug delivery. Nature materials, 12(11), pp.991-1003.

[10] Baetke, S.C., Lammers, T.G.G.M. and Kiessling, F., 2015. Applications of nanoparticles for diagnosis and therapy of cancer. The British journal of radiology, 88(1054), p.20150207.

[11] Godin, B., Sakamoto, J.H., Serda, R.E., Grattoni, A., Bouamrani, A. and Ferrari, M., 2010. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends in pharmacological sciences, 31(5), pp.199-205.

[12] Lammers, T., Aime, S., Hennink, W.E., Storm, G. and Kiessling, F., 2011. Theranostic nanomedicine. Accounts of chemical research, 44(10), pp.1029-1038.

[13] Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P. and Blakey, D.C., 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

[14] Bobo, D., Robinson, K.J., Islam, J., Thurecht, K.J. and Corrie, S.R., 2016. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceutical research, 33(10), pp.2373-2387.

Read more:
The Promising Future of Nanomedicine and... - The Doctor Weighs In

Global Nanotechnology for Healthcare Market Size, Status and Forecast 2019-2026

The latest report on Nanotechnology for Healthcare Market published by Reports And Markets provides a detailed analysis of the market. The objective of the report is to provide a comprehensive analysis of this market to its readers.

This report studies the Nanotechnology for Healthcare market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Nanotechnology for Healthcare market analysis segmented by companies, region, type and applications in the report.

New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

The key players covered in this study: Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International

Request a sample [emailprotected] https://www.reportsandmarkets.com/sample-request/global-nanotechnology-for-healthcare-market-size-status-and-forecast-2020-2026

Nanotechnology for Healthcare Market in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. A Nanotechnology for Healthcare Market provides an extensive view of size; trends and shape have been developed in this report to identify factors that will exhibit a significant impact in boosting the sales of Nanotechnology for Healthcare Market in the near future.

This report focuses on the global Nanotechnology for Healthcare status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nanotechnology for Healthcare development in United States, Europe, China, Japan, Southeast Asia, India, Central & South America.

Market segment by Type, the product can be split into

Market segment by Application, split into

The Nanotechnology for Healthcare market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Nanotechnology for Healthcare Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

The study objectives of this report are:

Get more details @:- https://www.reportsandmarkets.com/enquiry/global-nanotechnology-for-healthcare-market-size-status-and-forecast-2020-2026

Reasons for Buying this Report

Table of Contents:

Global Nanotechnology for Healthcare Market Size, Status and Forecast 2020-2026

Chapter One: Report Overview

Chapter Two: Global Growth Trends

Chapter Three: Market Share by Key Players

Chapter Four: Breakdown Data by Type and Application

Chapter Five: United States

Chapter Six: Europe

Chapter Seven: China

Chapter Eight: Japan

Chapter Nine: Southeast Asia

Chapter Ten: India

Chapter Eleven: Central & South America

Chapter Twelve: International Players Profiles

Chapter Thirteen Market Forecast 2020-2026

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Follow this link:
Nanotechnology for Healthcare Market to See Massive Growth by 2026| Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co,...

Prof. Shantanu Sur

Clarkson University President Tony Collins has announced that Shantanu Sur has been granted tenure and promoted from assistant professor to associate professor of biology in the School of Arts and Sciences.

A neuroscientist by training and working on the design of neural scaffolds and regeneration, Shantanu has expanded his research at Clarkson from studying airborne pathogens to build mathematical models for disease prediction. His recent work focuses on understanding the interactions between cancer cells and supramolecular biomaterials to identify supramolecular design principles that can induce regulated cell death. He is also collaborating with faculty from the Mathematics Department to develop a model of cancer cell movement to better understand the invasive behavior of cancer cells.

Shantanu has developed an extensive collaboration with the Canton-Potsdam Hospital to explore the possibilities of real-world applications of his research. He is working closely with Dr. Suresh Dhaniyala, Professor of Mechanical and Aeronautical Engineering, towards the detection and monitoring of pathogens causing healthcare-associated infections (HAIs) by using a network of portable, field-deployable sensors. In a different direction, he is working with Dr. Sumona Mondal, Professor of Mathematics and Dr. Eyal Kedar, Rheumatologist at the Canton-Potsdam Hospital to develop predictive models to aid in the diagnosis and prognosis of rheumatoid arthritis in a rural setting.

He has authored or co-authored more than twenty peer-reviewed publications and two book chapters, which include publications in prestigious journals such as Nature Communications, Nano Letters, ACS Nano, Angewandte Chemie, and Biomaterials. His research has been supported through external funding agencies such as NSF, NYSDEC, and HTR NEXUS-NY.

At Clarkson, he teaches courses in the area of clinical and health sciences. In addition to serving the Biology Department, he has been teaching core courses in the Department of Physical Therapy and the Department of Occupational Therapy. Two graduate students mentored by him received the prestigious NSF Graduate Research Fellowship.

Shantanu is a trained physician, completed his Bachelors in Medicine and Surgery from N.R.S. Medical College, University of Calcutta. He received his Masters in Medical Science and Technology and Ph.D. from the School of Medical Science and Technology, Indian Institute of Technology Kharagpur. Before joining Clarkson, he worked as a research scientist at the Brain Science Institute, RIKEN and a postdoctoral fellow at the Institute for BioNanotechnology in Medicine, Northwestern University.

Read the rest here:
Shantanu Sur Receives Tenure and Promotion to Associate Professor at Clarkson University - Clarkson University News

The UK gains benefits from the European Research Council that cannot be replaced, but there is good reason to be optimistic about the nation staying part of the programme despite Brexit, according to the funders new president.

The UK has been the number one [nation] in terms of funding received since the ERC was established in 2007, Mauro Ferrari toldTimes Higher Educationafter taking office last month. But the real benefit is bigger than that, he added.

Perhaps the biggest advantage of them all is that ERC grants strengthen the UKs position as a top destination for non-UK scientists, Professor Ferrari said. Think of all the great people that are in the UK with an ERC grant.

Science is all about people. You need the best people: you need to recruit them, you need to retain them. And I think the ERC has been a great instrument for the UK to do that.

Prestigious ERC grants for outstanding researchers, part of the European Unions wider framework programmes for research, have been described asmini-Nobel prizesand as the Champions League of research.

There is no certainty over whether the UK will seek to, or be allowed to, join the next framework programme, Horizon Europe, as an associated country when it starts in January 2021.

ERC grants are portable, but holders are expected to spend at least 50 per cent of their working time in an EU member state or associated country leading some in the UK to fear that the nation will miss out on attracting world-leading researchers if it does not associate to Horizon Europe.

While the UK will continue to attract and retain science talent, no matter what, because of its history and continuous investment, there is this bit that comes from the international connotation of the ERC that, I think, cannot be replaced, Professor Ferrari said.

His comments came as John Womersley, chief executive of the Science and Technology Facilities Council between 2011 and 2016, warns that there is great risk that the UK may choose not to associate to Horizon Europe.

Writing in THE, Professor Womersley now director-general of the European Spallation Source says that while UK-based researchers are keen to retain access to ERC funding, ministers are less likely to be keen on the two other larger pillars of Horizon Europe, covering challenge-based funding and the new European Innovation Council.

Professor Womersley warns that the EU is unlikely to allow cherry-picking of Horizon Europe, leading him to conclude that the UK was more likely to use the money it would otherwise contribute to the scheme tocreate a UK-based replacement for the ERC.

Asked by THE whether the UK could associate to the ERC, Professor Ferrari said that he cannot speculate on that. Thats the domain of a political negotiation, he said.

But given unanimous sentiment among UK and continental European scientists he had spoken with, he added: I would say there is good reason to be optimistic that some sort of reasonable construct will be reached that allows scientists to do their job in the best possible way.

ProfessorFerrari also discussed the ERCs role in building bridges between blue-sky research and innovation a link where he has personal experience as a pioneer of nanomedicine.

His 40-year academic career in the US began in engineering with a post at the University of California, Berkeley, then changed course following the death of his wife from cancer, after which heentered medical school at the age of 43to fight the disease.

Professor Ferrari retired as chief commercialisation officer at Houston Methodist Research Institute in 2019, but remains an affiliate professor with a lab at the University of Washington in Seattle.

I have returned [to Europe] for this job because I thought it was such an extraordinary and unique opportunity, he said.

The ERC, which evaluates proposals through international panels of leading scientists, is based on the principle that no individual, no agency, no office can actually envisage the future, what are the necessaryworld-changing breakthroughs in all of the fields of science, Professor Ferrari said. So we let scientists tell us.

Although European science is one of the global front-runners, he continued, there is no doubt about the fact that Europe has been lagging behind the United States when it comes to translation of great discoveries into innovation.

Professor Ferrari added that although the ERC by mandate is only doing blue-sky research, it has a role in addressing that by ensuring that research is best friends with innovation. We connect: we make sure our scientists are aware of whats happening in innovation, and make sure people on the innovation side are aware of what leading scientists are doing, he said.

john.morgan@timeshighereducation.com

Here is the original post:
ERC president 'optimistic' UK will stay in 'irreplaceable' fund - Times Higher Education (THE)

"The FDAs decision to grant Fast Track designation is not only important for the development of NBTXR3 activated by radiation therapy, which is now eligible for accelerated approval and priority review, but even more critically it underscores the unmet needs and limited options of patients with locally advanced head and neck cancer. The available public data and our development plans moving forward give us confidence that NBTXR3 could significantly improve treatment outcomes for patients. Fast Track development in head and neck cancer is a major step forward." Laurent Levy, CEO of Nanobiotix

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the "Company"), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Fast Track is a process designed to facilitate the development and accelerate the review of drugs for serious conditions and that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

A product that receives Fast Track designation is eligible for1:

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiotherapy radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory process for the clinical authorization of a phase II/III trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. The Company received FDA approval to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets)from any primary cancer eligible for anti-PD-1.

The other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. Furthermore, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany

Story continues

1https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005720/en/

Contacts

Communications Department Brandon Owens VP, Communications +1 (617) 852-4835contact@nanobiotix.com

Pascalyne Wilson Senior Manager, Corporate Marketing +33 (0) 1 70 61 00 18contact@nanobiotix.com

Investor Relations Department Noel Kurdi (US) Director, Investor Relations +1 (646) 241-4400investors@nanobiotix.com

Ricky Bhajun (EU) Senior Manager, Investor Relations +33 (0)1 79 97 29 99investors@nanobiotix.com

Media RelationsFrance TBWA Corporate Pauline Richaud + 33 (0) 437 47 36 42Pauline.richaud@tbwa-corporate.com

US RooneyPartnersMarion Janic +1 (212) 223-4017mjanic@rooneyco.com

Read more here:
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer - Yahoo Finance

Additional dates:Next Event:February 11, 2020

Dr. Michael SheetzWelch Professor of BiochemistryMolecular MechanoMedicine ProgramBiochemistry and Molecular BiologyUniversity of Texas Medical BranchGalveston, TX

Out of Touch: Depletion of Mechanosensors Drives Wound-Healing and Cancer

Tuesday, February 11, 202012:30 1:30 PMBRC, 10th Floor, Room 1060 A/B

Abstract: Loss of matrix rigidity sensing in tumor cells enables transformed growth. In over forty tumor lines tested, they lack rigidity sensing complexes because components are altered (about 60% had low Tpm 2.1). The rigidity sensing complex (about 2 m in length) contracts matrix adhesions by ~100nm; and if the force generated is greater than ~25 pN, then cells can grow (Wolfenson et al., 2016. Nat Cell Bio. 18:33). However, if the surface is soft, then the cells apoptose by DAPK1 activation (Qin et al., 2018 BioRxiv. 320739). Although tumor cells grow on soft surfaces, restoration of rigidity sensing restores rigidity-dependent growth (Yang, B. et al., 2020 Nature Mat. 19: 239). Surprisingly, mechanical stretch of transformed cancer cells activates apoptosis through calpain-dependent apoptosis (Tijore et al., 2018 BioRxiv. 491746). Thus, stretch sensitivity is a weakness of cancer cells related to transformation and not to the tissue type or other factors.

Bio: Prof. Michael Sheetz has a long history in mechanobiological research and was most recently the Director of the Mechanobiology Institute at the National University of Singapore. Prior to that he was a Professor at Columbia University where he headed a program in nanomedicine. At Duke University Medical School, he was Chair of Cell Biology from 1990 to 2000. He has received many awards including the Lasker Prize, Wiley and Massry Prizes.

Visit link:
Out of Touch: Depletion of Mechanosensors Drives Wound-Healing and Cancer - TMC News - Texas Medical Center News